Dengue
Dengue is an infection caused by the dengue virus of which there are four different types (serogroups) DENV-1, DENV-2, DENV-3 and DENV-4. The disease is spread through the bite of an infected mosquito. The mosquitoes that spread dengue usually breed in urban areas close to human habitation and are most active during daylight hours. Although unpleasant, dengue is usually a self-limiting illness. However, a small, but significant, number of people can develop more life-threatening infection (severe dengue).
The disease is common in the tropics. Affected areas include the Caribbean, South and Central America, Africa, Asia and the Pacific Islands. Although less common, outbreaks are increasingly being reported outside tropical areas, including in Europe, with locally acquired cases reported in Croatia, France, Italy, Madeira and Spain.
Dengue does not occur naturally in the United Kingdom (UK) but is reported in travellers returning from dengue affected areas. Cases of dengue in UK travellers are increasing, with most reported in travellers who visited Asia, Central and South America or the Caribbean. Country-specific information on dengue is available on our Country Information pages and current dengue outbreaks are listed on our Outbreak Surveillance section.
All travellers to dengue endemic countries are at risk of dengue infection. The chance of becoming infected with dengue is determined by several factors, including destination, length of exposure and season of travel. Risk is thought to be higher during periods of intense mosquito feeding activity (two to three hours after dawn and during the early evening). Travellers, who spend long periods in areas where dengue is common, are at increased risk, but even short-term visitors can be infected.
Approximately 40 to 80 percent of people infected with dengue remain symptom-free. If symptoms do occur, the illness usually begins abruptly with a high fever, and is often accompanied by a severe headache, muscle and joint pain, nausea, vomiting and a rash. Most infections are self-limiting, with a rapid recovery three to four days after the rash appears.
A small number of people develop more severe illness with symptoms which can include dangerously low blood pressure (shock), fluid build-up in the lungs and severe bleeding. There is no specific drug treatment for severe dengue illness, although hospital admission and careful management of fever, fluid balance and pain can help with recovery. If left untreated, severe dengue illness can be fatal. With good medical care, death due to severe dengue is typically less than one percent.
Prevention
Travellers can check our Country Information pages for information on the risk of dengue at their destination. Mosquito bite avoidance is recommended. As dengue is spread by day-biting mosquitoes, particular care with bite avoidance is advised during the day, especially around dawn and dusk.
A vaccine, Qdenga®▼ has been licensed in the UK for the prevention of dengue disease in individuals from 4 years of age.
The UK Joint Committee on Vaccination and Immunisation (JCVI) has advised that Qdenga®▼ vaccine can be considered for individuals aged 4 years of age and older who have had dengue infection in the past and are:
- planning to travel to dengue where there is a risk of dengue infection or areas with an ongoing outbreak of dengue
or
- exposed to dengue virus through their work, for example, laboratory staff working with the virus.
Guidance on use of Qdenga®▼ is available in the UKHSA 'green book' Immunisation against infectious disease, dengue chapter.
Qdenga®▼ is a live vaccine (it contains live, attenuated dengue virus) and cannot be given to travellers who are immunosuppressed (have a weakened immune system), pregnant or breastfeeding. This vaccine is also contraindicated (cannot be given) for those with hypersensitivity to any component of the vaccine and for children under four years of age.
Resources
- More detailed information on can be found in our dengue factsheet
- UKHSA: Dengue: guidance, data and analysis
- UKHSA: Dengue chapter 'green book' Immunisation against infectious disease
- Joint Committee on Vaccination and Immunisation (JCVI): Minutes of meeting 7 February 2024
- World Health Organization (WHO): Fact sheets: dengue and severe dengue
Explore more
Chikungunya
Chikungunya is a viral infection caused by the chikungunya virus (CHIKV) and is transmitted through the bite of an infected mosquito
Updated: 13 February 2025Middle East respiratory syndrome coronavirus
MERS-CoV is believed to have originated in bats and then spread to camels and has spread to humans from animals
Updated: 20 January 2025Marburg virus disease
Marburg virus is an animal-borne (zoonotic) virus that can cause a severe and often fatal haemorrhagic fever called Marburg virus disease (MVD)
Updated: 20 January 2025Lassa fever
Lassa fever is an infectious disease caused by Lassa virus, a member of the arenavirus family
Updated: 20 January 2025Crimean-Congo haemorrhagic fever
Crimean-Congo haemorrhagic fever (CCHF) is an infectious disease caused by the Crimean-Congo haemorrhagic fever virus (CCHFV)
Updated: 20 January 2025Recent News on Dengue
Mosquito and insect spread infections in the Caribbean
An increase in cases of mosquito and insect spread infections have been reported in the Caribbean region
Updated: 24 December 2024'Getting to grips with dengue and dengue vaccines' webinar- registration is now closed
Registration for our fifth webinar on 4 December 2024 is now closed
Updated: 13 November 2024Dengue 'green book' chapter published
A new dengue chapter in the 'green book' (Immunisation against infectious disease) has been published
Updated: 15 October 2024Insect spread illness reminder for pregnant travellers
Information and advice for pregnant women planning travel to countries with a risk of insect, mosquito and tick spread infections
Updated: 08 October 2024Recent Dengue Outbreaks
Dengue in Puerto Rico
As of 20 February 2025, a total of 6,291 dengue cases were reported in Puerto Rico for 2024. Cases remained above epidemic threshold in 2024, with active transmission also remaining above epidemic threshold through January 2025. DENV-1, DENV-2 and DENV-3 subtypes were identified; with DENV-3 the predominant circulating subtype, followed by DENV-1. Please see our Topics in Brief article for further details on dengue.
Dengue in Tonga
As of 20 February 2025, the Ministry of Health of Tonga declared an outbreak of dengue fever, with a total of 52 cases reported in Vava’u, Tongatapu and ‘Eua. Please see our Topics in Brief article for further details on dengue.
Dengue in Fiji
As of 3 February 2025, the Fiji Ministry of Health have reported 200 cases of dengue fever in the Western Division since the start of 2025. Please see our Topics in Brief article for further details on dengue.
Dengue in USA
On 25 November 2024, the first locally acquired case of dengue in Texas for 2024 was reported. As of 25 November 2024, 106 travel associated cases and one death were reported in Texas. This is the highest annual case count in Texas since 2002. Please see our Topics in Brief article for further details on dengue.
